ImpediMed’s L-Dex

June 20, 2022

Five-year, multi-site trial to assess lymphedema prevention concludes

Lymphedema study results could be a game-changer for breast cancer patients and survivors. The Vanderbilt-led trial found that patients with early detection who used L-Dex with additional intervention were less likely to progress to chronic lymphedema than patients monitored with a tape measure receiving the same intervention. 

By Nancy Wise